Coeptis Therapeutics Inc (COEP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Coeptis Therapeutics Inc stock (COEP) is currently trading at $10.40. Coeptis Therapeutics Inc PS ratio (Price-to-Sales) is 129.97. Analyst consensus price target for COEP is $3.00. WallStSmart rates COEP as Sell.
- COEP PE ratio analysis and historical PE chart
- COEP PS ratio (Price-to-Sales) history and trend
- COEP intrinsic value — DCF, Graham Number, EPV models
- COEP stock price prediction 2025 2026 2027 2028 2029 2030
- COEP fair value vs current price
- COEP insider transactions and insider buying
- Is COEP undervalued or overvalued?
- Coeptis Therapeutics Inc financial analysis — revenue, earnings, cash flow
- COEP Piotroski F-Score and Altman Z-Score
- COEP analyst price target and Smart Rating
Coeptis Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Coeptis Therapeutics Inc (COEP) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Coeptis Therapeutics Inc (COEP) Key Strengths (1)
Revenue surging 1564.00% year-over-year
Coeptis Therapeutics Inc (COEP) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 130.0x annual revenue
Very expensive at 6.3x book value
Very low institutional interest at 3.91%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Coeptis Therapeutics Inc (COEP) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 1564.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (129.97), Price/Book (6.28) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -372.10%, Operating Margin at -2253.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -372.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1564.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
COEP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
COEP's Price-to-Sales ratio of 129.97x trades at a deep discount to its historical average of 572.93x (36th percentile). The current valuation is 92% below its historical high of 1598.36x set in Feb 2021, and 1088% above its historical low of 10.94x in Sep 2024. Over the past 12 months, the PS ratio has compressed from ~602.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Coeptis Therapeutics Inc (COEP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Coeptis Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 263,560 with 1564% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 1564% YoY, reaching 263,560. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 119% of revenue (312,903) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Coeptis Therapeutics Inc maintain 1564%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Coeptis Therapeutics Inc.
Bottom Line
Coeptis Therapeutics Inc is a high-conviction growth story with revenue accelerating at 1564% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:27:07 AM
About Coeptis Therapeutics Inc(COEP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and markets brand-name and generic pharmaceuticals and cell therapy platforms for cancer patients. The company is headquartered in Wexford, Pennsylvania.